Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | FKBP1A | P62942 | 3/20 | 0.47 |
| ▸ | MMP1 | P03956 | 3/20 | 0.42 |
| ▸ | MMP13 | P45452 | 3/20 | 0.42 |
| ▸ | MMP3 | P08254 | 2/20 | 0.42 |
| ▸ | MMP7 | P09237 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3413278 | 0.86 | RAB9A (0.43) | RAB9ANPC1FKBP1AMMP1MMP13 | |
| SCHEMBL493720 | 0.81 | RAB9A (0.46) | RAB9ANPC1FKBP1AMMP1MMP13 | |
| SCHEMBL4124177 | 0.79 | RAB9A (0.50) | RAB9ANPC1FKBP1AMMP1MMP13 | |
| SCHEMBL493738 | 0.78 | RAB9A (0.43) | RAB9ANPC1MMP1MMP13MEN1 | |
| SCHEMBL4119477 | 0.78 | BDKRB1 (0.47) | MMP1MMP13MMP3MMP7MEN1 | |
| SCHEMBL3408443 | 0.77 | BDKRB1 (0.43) | FKBP1ABDKRB1 | |
| SCHEMBL5131956 | 0.76 | FKBP1A (0.47) | RAB9ANPC1FKBP1AMMP1MMP13 | |
| SCHEMBL4133018 | 0.76 | MMP1 (0.56) | RAB9ANPC1FKBP1AMMP1MMP13 | |
| SCHEMBL493436 | 0.76 | RAB9A (0.45) | RAB9ANPC1FKBP1AMMP1MMP13 | |
| SCHEMBL492883 | 0.75 | ALDH1A1 (0.46) | RAB9ANPC1MMP1MMP13MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090253669-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-10-08 | — | — | US | claimed |
| EP-2257527-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2010-12-08 | — | — | EP | disclosed |
| US-20090253669-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-10-08 | — | — | US | disclosed |
| WO-2009115257-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253669-A1 | Substituted Sulfonamide Compounds | SULT2A1, STS, SULT1A1 | RAB9A 2485/4885NPC1 2399/4885FKBP1A 891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.